Breaking News, Collaborations & Alliances

Impact Therapeutics, Eikon Partner to Develop PARP1 Selective Inhibitors

Eikon will co-develop, register, manufacture and commercialize IMP1734 and other PARP1 selective inhibitors.

IMPACT Therapeutics, a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, and Eikon Therapeutics, a biotechnology company advancing breakthrough therapeutics, entered into a global license and collaboration agreement for PARP1 selective inhibitors including IMP1734, which is anticipated to enter a Phase I clinical study in 2023. Under the collaboration, Eikon received an exclusive license from Impact to co-dev...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters